CanVirex03

CanVirex03 is an investigational oncolytic virus therapy currently in the discovery or pre-clinical stage of development by CanVirex. It is part of a portfolio of measles virus (MeV) vectors engineered for cancer immunotherapy. The therapy utilizes the company's proprietary measles virus platform, which is designed to selectively infect and lyse tumor cells (oncolysis) while inducing a systemic anti-tumor immune response. The platform often incorporates 'stealth' modifications to the viral envelope to evade neutralizing antibodies, potentially facilitating systemic delivery and repeated dosing. While specific details regarding the payload or exact tumor indication for CanVirex03 have not been publicly disclosed, it follows the lead candidate CanVirex01 in a pipeline focused on treating various solid tumors.